Another China-Developed PD-1 Inhibitor Makes Its Case in NSCLC
Adding the investigational PD-1 checkpoint inhibitor toripalimab to chemotherapy in first-line significantly improved progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients without EGFR/ALK mutations, according to results from a study conducted in China. Median PFS improved from 5.6 months with chemotherapy alone to 8.4 months with the toripalimab-based combination (HR 0.49, 95% […]